/analysis/6244/
Market Focus
US stock advanced on Thursday amid risk-on market sentiment, closing at all-time high and rose for a third day as investors considered that the economic recovery can resist the impact of the Omicron coronavirus variant. On Thursday, Merck & Co.’s Covid-19 pill was cleared by US regulators, giving high-risk patients another option for emergency use. Early trials also suggest that Merck’s molnupiravir could reduce mortality and hospitalisation rates in at-home patients by as much as 50%. In fact, people infected with Omicron are 50% to 70% less likely than those with Delta to be admitted to hospitals. Therefore, the positive news about Omicron variant and the announcement of the Merck & Co. approval both acted as a tailwind for the stock market. On top of that, the above news has also eased pressure on European authorities to lockdown their economies in order to curb epidemic transmission.
The benchmarks, S&P 500, Nasdaq 100 and the Dow Jones Industrial Average both rose on Thursday as risk appetite in US equities market has been boosted due to the news of the recent approval of two at-home Covid-19 treatment pills. Trading volume was low ahead of the Christmas holidays. S&P 500 was up 0.6% on a daily basis and the Dow Jones Industrial Average also advanced with a 0.5% gain for the day. Nine out of eleven sectors stayed in positive territory as the consumer discreet and industrials sectors are the best performing among all groups, rising 1.24% and 1.16%, respectively. The Nasdaq 100 climbed the most with 0.8% gain on Thursday and the MSCI World index rose 0.8%. The S&P 500 CBOE volatility index fell another half a point and trades at monthly lows close to 18.00 level.
Main Pairs Movement:
The US dollar declined on Thursday, staying in negative territory for the fourth consecutive day amid risk-on market mood despite rising US bond yields. The DXY index reached a daily top in late European session, then pulled back to near 96.00 level while surrendered most of its intraday’s gains. The US Food and Drug Administration announced that it had approved a second Covid-19 treatment pill for at-home use, which helped stoke risk appetite on Thursday and weighed on the safe-haven greenback. On economic data’s front, US consumer sentiment increased in December and new homes sales also climbed to a seven-month high.
GBP/USD advanced 0.43% on Thursday amid bearish momentum witnessed in US dollar across the board. The news that the UK was unlikely to implement tougher Covid-19 curbs after Christmas had lend support to the British pounds. The cable touched a daily high above 1.343 level in early American session, now trading at 1.3409 at the time of writing. Meanwhile, EUR/USD dropped to a daily low under 1.130 level but then rebounded modestly to offset some of its intraday’s losses. The pair was down 0.02% for the day.
Gold advanced and touched a daily top above $1810 during American session, as the broad US dollar weakness continued to pushed the precious metal higher. Meanwhile, WTI oil surged almost 1.0% for the day amid optimism that the hit to oil’s demand from Omicron won’t be as bad as initially feared.
Technical Analysis:
The precious metal, gold, steadily trades above 1800, trading at 1809 as the time of writing. Gold looks to head toward the immediate hurdle at 1815, retest its monthly high on the 4- hour chart. The resistance at 1815 is consider as a strong static barrier as gold attempts it three times within 2 months, but it ends up failing to break through. Thus, a break though the level would likely signal a firmer upward momentum. However, it would be difficult as the RSI has almost reached the overbought readings. On the downside, if gold falls below 1800, then it will turn to neutral mode from bullish mode. Overall, the risk is skewed to the upside as long as gold can hold above 1800.
Resistance: 1815, 1829, 1848
Support: 1800, 1782, 1770, 1765, 1753.
The major indices, including Nasdaq 100, rose for a third successive day as the markets less fear the Omicron and celebrate for Christmas. From the technical aspect, a three consecutive day upside momentum has brought Nasdaq 100 back to a bullish stance on the daily chart as it trades above all 5, 10, 20, 60 SMAs, suggesting a bullish trend. Nasdaq 100 has overall reclaim strength as the MACD is turning from negative to positive while the RSI is still far away from the overbought territory, entailing that buyers are in control. Most importantly, the double bottom pattern has been formed, which implies that sellers have given up and they are unable to push price downward. Consequently, the formation of the double bottom signifies a potential bullish reversal signal, heading to the next resistance at 16457, followed by the peak, 16796.
Resistance: 16457
EURUSD remains under modest price action, slightly turning upside after the US Core PCE Inflation jumped to 4.7% in November. From the technical perspective, EURUSD is still stuck in 1.1233- 1.1357 price range of the late November slide. In the near- term, the currency pair leans to bullish side as it trades within the upper bounce of Bollinger band, suggesting a potential upside momentum. In the meantime, the price action continues to remain above the 20 and 50 SMAs. To the upside, EURUSD needs to climb above the resistance at 1.1357 in order to turn from neutral- to- bullish, followed by the resistance at 1.1462. On the flip side, the bearish case can gain momentum on a break below the SMAs and 1.1233, followed by the support at 1.1186.
Resistance: 1.1357, 1.1462, 1.1548
Support: 1.1233, 1.1186
Economic Data: No Economic Calendar Due to Christmas Eve
Currency |
Data |
Time (GMT + 8) |
Forecast |
|
Education
Risk Warning: Trading CFDs carries a high level of risk and may not be suitable for all investors. Leverage in CFD trading can magnify gains and losses, potentially exceeding your original capital. It’s crucial to fully understand and acknowledge the associated risks before trading CFDs. Consider your financial situation, investment goals, and risk tolerance before making trading decisions. Past performance is not indicative of future results. Refer to our legal documents for a comprehensive understanding of CFD trading risks.
The information on this website is general and doesn’t account for your individual goals, financial situation, or needs. VT Markets cannot be held liable for the relevance, accuracy, timeliness, or completeness of any website information.
Our services and information on this website are not provided to residents of certain countries, including the United States, Singapore, Russia, and jurisdictions listed on the FATF and global sanctions lists. They are not intended for distribution or use in any location where such distribution or use would contravene local law or regulation.
VT Markets is a brand name with multiple entities authorised and registered in various jurisdictions.
· VT Global Pty Ltd is authorised and regulated by the Australian Securities & Investments Commission (ASIC) under licence number 516246.
· VT Global is not an issuer or market maker of derivatives and is only allowed to provide services to wholesale clients.
· VT Markets (Pty) Ltd is an authorised Financial Service Provider (FSP) registered and regulated by the Financial Sector Conduct Authority (FSCA) of South Africa under license number 50865.
· VT Markets Limited is an investment dealer authorised and regulated by the Mauritius Financial Services Commission (FSC) under license number GB23202269.
Copyright © 2024 VT Markets.